Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
NHS England and NHS Improvement (NHSE&I) have issued information on the first in a series of psychological support for all NHS staff, including those working in primary care, during the COVID-19 outbreak. NHSE&I note the importance of healthcare workers looking after their own health and wellbeing, whilst supporting patients and their family. The initial offer...
PSNC has today (27th March) published a list of the possible action points that we are in urgent negotiations with the NHS and Government about to ensure that community pharmacy teams are fully supported in their response to the COVID-19 pandemic. These include discussions on an urgent funding rescue package, recognising the enormous financial pressures...
This briefing outlines the scope of the urgent discussions that are ongoing between PSNC, the Department of Health and Social Care (DHSC), and NHS England & NHS Improvement (NHSE&I) to ensure that community pharmacy teams have the support they need to play their role in the response to the COVID-19 pandemic. PLEASE NOTE: This document...
Whilst community pharmacies are experiencing unprecedented demand during the COVID-19 pandemic, they are reminded of the importance of submitting their end of month prescription bundle and FP34C. The monthly submission bundle and its associated FP34C submission document is effectively a pharmacy’s invoice to the NHS for payment and without it no payment can be made....
Department of Health and Social Care (DHSC) has today granted the following list of price concessions: Drug Pack size Price concession Clarithromycin 250mg/5ml oral suspension 70ml £5.77 Erythromycin 250mg gastro-resistant tablets 28 £8.85 Fenofibrate micronised 267mg capsules 28 £2.80 Ibuprofen 400mg tablets 24 £1.25 Ibuprofen 400mg tablets 84 £4.38 Isosorbide mononitrate 20mg tablets 56 £1.48...
Updated 25/03/2020 MHRA has today asked that healthcare professionals make permanent the recommended actions originally communicated below. Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for Diamorphine Hydrochloride Powder for Reconstitution and Injection 5mg and 10mg ampoules. There are two suppliers of diamorphine hydrochloride 5mg and 10mg in the...
PSNC, working closely with NPA, CCA and AIM, has published guidance to help support and maintain the community pharmacy network during the response to the COVID-19 pandemic. These are unprecedented times and exceptional measures may be required to ensure patient and public safety, as well as the safety and welfare of the pharmacy team. The...
Class 4 Medicines Defect Information – Zamadol SR 50 mg prolonged-release hard capsules (Mylan UK Healthcare Ltd) Drug alert number: (EL(20)A/18) Date issued: 25 March 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Zamadol SR 50 mg prolonged-release hard capsules (Mylan UK Healthcare Ltd)...
The NHS has today launched a major campaign to “rally the troops” for the war on coronavirus, with volunteers being asked to help vulnerable people stay safe and well at home. The nation is looking for up to 250,000 volunteers to help up to 1.5 million people who have been asked to shield themselves from...
PSNC recommends that in these times where there could a risk of temporary closure at your pharmacy caused by COVID-19 to consider the following EPS timing submission tips: Send EPS dispense and claim messages promptly and often, preferably daily. This helps in case of a temporary closure becoming required or a technical outage happening. This...
There is no evidence from clinical or epidemiological studies that treatment with ACE-I or ARBs might worsen COVID-19 infection.
There are different regulations which apply to devices and equipment including hand gels and PPE (personal protective equipment)
Fast-track approval of medical devices during COVID-19 outbreak
How to get in touch with the MHRA during this period.
Keep up to date with the latest information from the UK GLP monitoring authority.
This guidance sets out the clinical requirements based on the consensus of what is ‘minimally acceptable’ performance in the opinion of the anaesthesia and intensive care medicine professionals and medical device regulators.
Details of the Yellow Card scheme, which is the system for recording adverse incidents with medicines and medical devices in the UK.
MAHs should review their manufacturing processes to identify and, if found, to mitigate risk of presence of nitrosamine impurities.
Recent media reports have suggested that chloroquine can protect patients from coronavirus or treat COVID-19, the illness caused by a coronavirus.
Sets out medicines that cannot be parallel exported from the UK because they are needed for UK patients.
What manufacturers need to do
Mylan UK Healthcare Ltd has informed us that the GTIN barcode applied on the below batches is incorrect.
If pharmacies wish to ‘pack down’ larger packs of a medicinal product, they need to follow these instructions
How investigators and sponsors should manage clinical trials during COVID-19
How to notify MHRA of your intention to carry out a clinical investigation for CE marking.
Summary List of field safety notices (FSNs) from medical device manufacturers from 16 to 20 March 2020
Current listing of UK brokers authorised to broker human medicines, including company name, registration and address.
We will only be conducting essential inspections. We are expecting organisations to maintain GxP compliance.
How to contact MHRA for specific services or enquiries.
Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.
Post-Transition period action deadlines will go beyond 2020 by at least 1 year.
This is the hub for all the Veterinary Medicines Directorate's communications on the Transition Period.
Request to notify the VMD if you are planning to send items through the post.
The launch of SMArt a new charity to improve the regulation of veterinary medicines worldwide.
VMD assures stakeholders that we continue to provide our services to regulate veterinary medicines.
The VMD switchboard is now up and running.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Details of seizure of veterinary medicines at Border Force, Newcastle airport, following a routine search. Published in March 2020
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Product defect recall alert for Prednidale 5 mg Tablets (Vm 10434/4009) by Dechra Ltd
Reporting against VMD published standards up to 29 February 2020.
Update: Web services, such as the Special Imports System and the PID have now been restored
How to complete and submit the turnover declaration form as the holder of a UK marketing authorisation.
From 1 April emails sent to the VMD's old email address will no longer be re-directed to the current email address.
Summary of the annual review 2018 of veterinary pharmacovigilance in the UK.
A review of adverse events following the use of veterinary medicines reported in 2018
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
Animal medicines seizure notices: Published following the conclusion of an investigation case.
Marketing Authorisations Information Service (MAVIS) Hub edition 113
Thermo Fisher has also announced that it has received the CE mark in the European Union for its diagnostic test.
Despite available treatments, multiple myeloma remains an incurable malignancy, and is associated with significant patient burden.
While the opioid epidemic in the USA is well documented, Europe also has an estimated 1.3 million high-risk opioid users.
Evox will offer its preclinical programme in Niemann-Pick disease type C for development, and a second new programme directed at another undisclosed rare disease.
There are about six million people in Europe with epilepsy, and approximately 40% of adults with focal-onset seizures continue to experience seizures.
The FDA has also granted Gilead's wishes to withdraw orphan drug designation for remdesivir under current circumstances.
Astellas has confirmed that it will make an upfront cash payment of $80 million to CytomX.
The vaccine met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.
Previously the licence referred to “physicians”, prompting confusion over who is able to inject the treatment.
STING is known to play a role in activating the innate immune system in auto-inflammatory diseases.
Regular hepatitis C screening and improved access to new treatments has potentially contributed to greatly reducing the transmission of the infection.
PHE has also been awarded $500,000 by the US FDA to bolster the international response.
siRNA are double-stranded RNA molecules that offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production.
Roche also reported that safety for Venclexta/Venclyxto with azacitidine appeared consistent with the known safety profile of these medicines.
The current recorded case count for COVID-19 (coronavirus) in the UK has hit 6,650, with 335 deaths and 135 recoveries.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
